Table 2.

Summary of studies on the use of locoregional therapy for combined hepatocellular cholangiocarcinoma.

Reference	Patients	Treatment	Responders	Median PFS (Months)	Median OS (Months)	Tumor Progression (%)
Fowler et al. (2015) [63]	79	TACE (6)	-	-	-	2 (30%)
		TARE (6)	47%	16	8.3	3 (50%)
		HAI pump (6)	-	-	-	0
		Systemic chemotherapy (28)	-	-	-	15 (44%)
		Surgery (33)	35 (70%)	16	12.3	0
Kim et al. (2010) [84]	50	TACE	35 (70%)	-	12.3	15(30%)
Chan et al. (2017) [89]	10	TARE	60% partial response and 40% stable disease	-	10.2 from 1st RE treatment and 17.7 from initial diagnosis	-
Na et al. (2018) [85]	42	TACE	Globally enhancing cHCC-CC—36% Peripherally enhancing cHCC-CC—0% HCC—35.6%	Globally enhancing cHCC-CC—4.7 Peripherally enhancing cHCC-CC—2.1 HCC—9.7	Globally enhancing cHCC-CC—52.8 Peripherally enhancing cHCC-CC—12.4 HCC—67.5	cHCC-CC—37(88.1%)